These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34796121)

  • 1. First Case of Subcutaneous Mycoses Caused by
    Hu F; Wang C; Wang P; Zhang L; Jiang Q; Al-Hatmi AMS; Blechert O; Zhan P
    Front Cell Infect Microbiol; 2021; 11():711768. PubMed ID: 34796121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First neonatal case of fungaemia due to Pseudozyma aphidis and a global literature review.
    Prakash A; Wankhede S; Singh PK; Agarwal K; Kathuria S; Sengupta S; Barman P; Meis JF; Chowdhary A
    Mycoses; 2014 Jan; 57(1):64-8. PubMed ID: 23834440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudozyma spp. human infections: A systematic review.
    Telles JP; Ribeiro VST; Kraft L; Tuon FF
    Med Mycol; 2021 Jan; 59(1):1-6. PubMed ID: 32343341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
    Lei HL; Li LH; Chen WS; Song WN; He Y; Hu FY; Chen XJ; Cai WP; Tang XP
    Eur J Clin Microbiol Infect Dis; 2018 Jun; 37(6):1099-1102. PubMed ID: 29536323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triazole antifungal agents in invasive fungal infections: a comparative review.
    Lass-Flörl C
    Drugs; 2011 Dec; 71(18):2405-19. PubMed ID: 22141384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin].
    van 't Wout JW; Kuijper EJ; Verweij PE; Kullberg BJ
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1679-84. PubMed ID: 15453120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal agents.
    Chen SC; Sorrell TC
    Med J Aust; 2007 Oct; 187(7):404-9. PubMed ID: 17908006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
    Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
    J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
    Pande A; Non LR; Romee R; Santos CA
    Transpl Infect Dis; 2017 Apr; 19(2):. PubMed ID: 28099778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium.
    Badali H; Khodavaisy S; Fakhim H; de Hoog GS; Meis JF; Chowdhary A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7818-22. PubMed ID: 26369976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antifungal agents in children.
    Steinbach WJ
    Pediatr Clin North Am; 2005 Jun; 52(3):895-915, viii. PubMed ID: 15925667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.